Asunción Martínez

Articles translated into Spanish by Asunción Martínez

• The director’s cut: how CAG repeats change the editing of genetic messages
• Huntington's Disease Therapeutics Conference 2024 - Day 1
• CRISPR-based drugs: one giant leap for mankind
• Drug to treat movement symptoms of HD approved by FDA
• Sad news from Novartis: dosing suspended in VIBRANT-HD trial of branaplam
• Hunting for balance: how the huntingtin protein compensates in HD
• Update on the PTC Therapeutics PIVOT-HD Trial
• Disappointing news from Novartis about branaplam and the VIBRANT-HD trial
• uniQure gets the green light to resume testing HD gene therapy
• Focusing in on fibrils; scientists give us a glimpse of huntingtin protein clumps
• Hereditary Disease Foundation (HDF) conference 2022 – Day 1
• Forward momentum for Roche and Wave in latest news about huntingtin-lowering trials
• Revisiting vitamin therapy for HD
• KINECT-HD trial shows valbenazine improves involuntary movements in Huntington's disease
• Real talk: Q&A with Roche about GENERATION-HD1
• “Seeing” the toxic huntingtin protein in people with HD
• Updates from the EHDN Meeting 2021
• Scientists identify precisely how pridopidine works in models of Huntington’s disease
• Does blood hold the key to testing treatments earlier in HD patients?
• A first for CRISPR gene editing could have wider applications for human disease
• Unpacking recent gene therapy press
• What does COVID-19 mean for Huntington’s disease families and HD research?
• An Updated Trial Design for Roche's Huntingtin Lowering Trial
• Exciting new Huntingtin lowering tool described
• Could molecular handcuffs lower the protein that causes Huntington's disease?
• Unpacking Wave's PRECISION-HD2 huntingtin-lowering trial announcement
• Roche announces details of its 'pivotal' huntingtin-lowering study
• Details emerge of first Huntington’s disease gene therapy clinical trial
• New molecule can reverse the Huntington's disease mutation in lab models
• Huntington’s disease therapeutics conference 2020 - Day 1
• Huntington’s disease therapeutics conference 2020 - Day 2
• Huntington’s disease therapeutics conference 2020 - Day 3
• Screening the entire genome for new drug targets for HD
• The third dimension: using minibrains to understand brain development changes in HD
• Disappointing news from LEGATO-HD trial of laquinimod in Huntington's disease
• Ask the expert: Q&A on the huntingtin-lowering trial program
• HDBuzz Enrolls in Enroll-HD
• Switch off the genome editor when you’re done
• A new way of thinking about trials to prevent Huntington's disease
• Success! ASO drug reduces levels of mutant protein in Huntington's disease patients
• A step forward for gene editing: CRISPR-Cas9 and HD
• Treasure your exceptions - using outliers to understand Huntington's disease onset and progression
• Looking Past the Spin: Results from a Clinical Trial of Cysteamine
• Liftoff: First humans treated with gene silencing drugs for HD!
• EuroBuzz 2014: day three
• New results bring BDNF therapies into focus
• Gone fishing: protein network screen identifies new therapeutic targets in Huntington's disease
• EuroBuzz 2014: day two
• EuroBuzz 2014: day one
• Joint HDBuzz Prizewinner: Yeast studies suggest a new way to protect cells from 'oxidative damage'
• Prana announces results of Reach2HD trial of PBT2 for Huntington's disease
• Sleep, cilia and HD
• Splicing with danger: a new way of thinking about the harmful Huntington's disease protein
• Huntington's Disease Therapeutics Conference 2014: day 3
• Huntington's Disease Therapeutics Conference 2014: day 1
• Huntington's Disease Therapeutics Conference 2014: day 2
• Is a new Huntington’s Disease drug study on the right Trk?
• Does high-dose creatine "slow the onset" of Huntington's Disease?
• Could a 'brain shuttle' get Huntington's disease drugs to where they're needed?
• Could muscle problems help explain movements in Huntington’s Disease patients?
• Prana Biotech publishes Huntington's disease animal model data for PBT2
• 'Guard dog' proteins reveal surprising connections between Huntington's disease and other brain disorders
• Coming soon from the 2013 Huntington's Disease World Congress: Buzzilia!
• Coming Soon: EuroBuzz 2012
• Dyeing to prevent dying? Methylene blue beneficial in Huntington's disease mice
• No surprises in published results from HART study of Huntexil for Huntington's disease
• Lithium with a twist gets second chance for HD
• Landmark study puts Huntington's disease trials on TRACK
• Giving Huntington's disease the finger? Two teams report success for zinc-finger drugs in cells and mice
• High-power brain scans reveal sodium changes in HD
• Interview: Alice and Nancy Wexler
• Illuminating findings in blood cells from Huntington's disease patients
• HDBuzz Special Feature: Huntington's disease and sleep
• Mapping the neighborhood: huntingtin's new protein partners
• HDBuzz Prize runner-up 2012: Fruit flies, faulty connections and Huntington's disease
• Targeting oxidative stress in Huntington's Disease
• Of mice and men: using animal models to study Huntington's disease
• Does the HD mutation affect children's growth?
• 'Induced' stem cells make exciting advances
• ASO gene silencing reaches further, lasts longer
• Phosphodiesterase inhibitors: new HD drugs entering trials soon
• Video: What’s new in Huntington's disease research 2012
• Shooting the messenger with single-stranded RNA gene silencing
• EuroBuzz Video: Day 1
• Interview: CHDI's scientific team
• Exercise increases cellular recycling
• What's the connection between Huntington's Disease and cancer?
• The HDBuzz Prize for young science writers
• Closing the care gap: new guidelines for HD care
• Stem-cell neurons make the right connections
• 2012 Therapeutics Conference: a retrospective
• Coming soon: HD Therapeutics Conference 2012
• HDAC inhibitor drug protects memory in HD mice
• Turning down the volume with dantrolene helps HD mice
• Gene silencing takes a targeted step forward
• TRACK-HD reveals changes in HD mutation carriers, empowering future trials
• Prana Biotech's new trial of PBT2 in Huntington's disease: the lowdown
• HD Therapeutics Conference 2012 Updates: Day 1
• Chinese Huntington’s Disease Network launched
• New analysis suggests 'small' CAG length doesn't matter after all
• Mutant yeast highlights crucial CAG-reading protein
• Cut-and-paste DNA: fixing mutations with 'genome editing'
• Special 'brain fat' injection helps HD mice
• Gene therapy meets stem cells in liver disease success
• Bone marrow transplantation in Huntington's Disease
• HDYO! Huntington's Disease Youth Organization goes live
• Could mesenchymal stem cells deliver gene silencing drugs?
• New experiments clarify the role of SIRT1 in HD - or do they?
• Double success for huntingtin RNAi gene silencing
• Caffeine, cannabis and caution
• Making babies: having a family, the HD way
• Re-routing the huntingtin protein inside cells
• 2011 - a year in Huntington's disease research
• Not all in your head: digestive problems in HD
• Meet the enemy: neutron ray reveals HD protein structure
• Improving Huntington's disease clinical trial recruitment through patient and family education
• Chubby mice reveal the importance of the hypothalamus in Huntington's disease
• HD just got cilia
• Melatonin treatment success in HD mice
• New antibody reveals dangerous parts of huntingtin protein
• Ten golden rules for reading a scientific news story
• Huntexil hits the headlines again
• Safety trials add crucial piece to gene silencing jigsaw
• The genetic 'gray area' of Huntington's disease: what does it all mean?
• Dimebon fails in late-stage human HD clinical trial
• Protein-folding drug helps HD mice... for a while
• HDAC inhibitors and a possible 'blood biomarker'
• HD World Congress 2011: a retrospective
• Successful gene therapy trial in Parkinson’s Disease gives hope for HD
• Therapeutics conference videos now online
• Coming soon from the HD World Congress: Oz Buzz!
• Oz Buzz Video: Day 2
• Gene silencing for HD: the story so far
• A back-to-front hidden message in the HD gene?
• Interview: Graeme Bilbe, Global Head for Neuroscience at Novartis
• Stem cells and HD: past, present and future
• CHDI Report: Day 1
• Interview: CHDI Management
• KMO inhibitor drug improves lifespan of Huntington's disease mice
• Does HD cause brains to develop differently?
• Focused drug screening leads to improved drugs to increase the rate of cellular recycling
• Getting the data out – a new scientific journal just for HD
• FDA: further trial needed for Huntexil approval in HD
• Are there genetic connections between neurodegenerative diseases?
• Two large HD observational studies – COHORT and Registry – merge to create ENROLL-HD
• Anti-nausea drug helps cells with the HD mutation stay healthy in a surprising way
• Huntexil update: EMA asks for further trial
• 'Floating' gene-silencing drugs into the brain with exosomes
• What do sheep brains have to do with HD?
• CHDI Report: Day 3
• CHDI Report: Day 2
• Dimebon: disappointing in Alzheimer’s but might work in HD
• TRACK-HD reveals significant changes in pre-symptomatic HD mutation carriers and patients
• HDBuzz takes your questions to the annual therapeutics meeting of CHDI
• Frequently asked questions, January 2011
• Memantine in HD: dose is everything
• Huntexil for symptoms of Huntington's disease: where are we now?
• Welcome to HDBuzz